Literature DB >> 12611755

A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease.

Paul S Aisen1, Susan Egelko, Howard Andrews, Ramon Diaz-Arrastia, Myron Weiner, Charles DeCarli, William Jagust, Joshua W Miller, Ralph Green, Karen Bell, Mary Sano.   

Abstract

OBJECTIVE: Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD).
METHODS: Authors used an open-label trial of folic acid, vitamin B(12), and vitamin B(6), in combination for 8 weeks, with measurement of plasma homocysteine levels in the fasting state and after methionine-loading. A total of 69 subjects with AD were enrolled, including 33 who were taking standard multivitamin supplements; 66 were available at 8-week follow-up.
RESULTS: The high-dose vitamin regimen was associated with a significant reduction in fasting and post-methionine-loading homocysteine. Reductions were greater in the subgroup not using multivitamins, but were also significant in the multivitamin users.
CONCLUSION: High-dose vitamin supplementation reduces homocysteine levels in patients with AD. The effect of supplementation on rate of cognitive decline will be assessed later in a randomized, double-blind study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611755

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  15 in total

1.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

Authors:  Joseph F Quinn; Rema Raman; Ronald G Thomas; Karin Yurko-Mauro; Edward B Nelson; Christopher Van Dyck; James E Galvin; Jennifer Emond; Clifford R Jack; Michael Weiner; Lynne Shinto; Paul S Aisen
Journal:  JAMA       Date:  2010-11-03       Impact factor: 56.272

2.  Relation of plasma homocysteine to plasma amyloid beta levels.

Authors:  José A Luchsinger; Ming-Xin Tang; Joshua Miller; Ralph Green; Pankash D Mehta; Richard Mayeux
Journal:  Neurochem Res       Date:  2006-12-27       Impact factor: 3.996

Review 3.  Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage.

Authors:  Bruce N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

4.  Reduced risk of Alzheimer's disease with high folate intake: the Baltimore Longitudinal Study of Aging.

Authors:  María M Corrada; Claudia H Kawas; Judith Hallfrisch; Denis Muller; Ron Brookmeyer
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

Review 5.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 6.  Pharmacology of epigenetics in brain disorders.

Authors:  Pritika Narayan; Mike Dragunow
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

7.  High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Authors:  Paul S Aisen; Lon S Schneider; Mary Sano; Ramon Diaz-Arrastia; Christopher H van Dyck; Myron F Weiner; Teodoro Bottiglieri; Shelia Jin; Karen T Stokes; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2008-10-15       Impact factor: 56.272

8.  Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging.

Authors:  Mary N Haan; Joshua W Miller; Allison E Aiello; Rachel A Whitmer; William J Jagust; Dan M Mungas; Lindsay H Allen; Ralph Green
Journal:  Am J Clin Nutr       Date:  2007-02       Impact factor: 7.045

9.  The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps.

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Exp Gerontol       Date:  2010-01-11       Impact factor: 4.032

10.  Souvenaid®: a new approach to management of early Alzheimer's disease.

Authors:  C W Ritchie; J Bajwa; G Coleman; K Hope; R W Jones; M Lawton; M Marven; P Passmore
Journal:  J Nutr Health Aging       Date:  2014-03       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.